UBS/CALL/ELI LILLY & CO/900.001/0.01/20.12.24 | Real-time Bid/Ask 07:59:38 06/06/2024 pm IST | ||
| 0.58 CHF / 0.59 CHF | +8.33% |
|
| 1 month | +86.21% | ||
| 3 months | +10.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 0.54 | +10.20% |
Delayed Quote Swiss Exchange
Last update June 03, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYGBU | |
| ISIN | CH1312533784 |
| Date issued | 08/01/2024 |
| Strike | 900 $ |
| Maturity | 20/12/2024 (197 Days) |
| Parity | 100 : 1 |
| Emission price | 0.11 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.57 CHF |
|---|---|
| Lowest since issue | 0.12 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.75% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.8
USD
Average target price
852.5
USD
Spread / Average Target
+2.50%
- Stock Market
- Warrants
- LLYGBU Warrant
